article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

They do not induce ‘graft versus host’ disease when transplanted for allogeneic therapy and there appears little sign of immune rejection. Peripheral blood NK cells have been used in allogeneic cancer therapies and shown to be safe. developing immune stem cell therapies for treating ovarian and gastric cancer.

Therapies 118
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 2 of 3

Drug Target Review

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

Drugs 69
article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge. Raminderpal earned his PhD in semiconductor modelling in 1997.

RNA 52
article thumbnail

Antibiotic Therapy Before Age 2 May Affect Child Health

The Pharma Data

1, 2003, and Dec. Zaira Aversa, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a population-based cohort study involving children born in Olmsted County, Minnesota, between Jan. 31, 2011, to examine the impact of antibiotic exposure in the first two years of life.

article thumbnail

Inavolisib

New Drug Approvals

3] Primary endocrine resistance was defined as relapse while on the first two years of adjuvant endocrine therapy (ET) and secondary endocrine resistance was defined as relapse while on adjuvant ET after at least two years or relapse within twelve months of completing adjuvant ET. [3] New Drug Therapy Approvals 2024 (PDF).

FDA 57
article thumbnail

FDA accepts application for self-administered Xolair use

The Pharma Data

Approximately 460,000 patients in the US have been treated with Xolair since its first approval for allergic asthma back in 2003. If approved, patients will be able to self-administer Xolair once the therapy has been established and closely observed in a healthcare setting. Source link.

FDA 52